通化金馬(000766.SZ):2019年業績盈轉虧至20.42億元
格隆匯4月28日丨通化金馬(000766.SZ)披露2019年年度報告,實現營業收入19.77億元,同比下降5.60%;歸屬於上市公司股東的淨虧損20.42億元,上年同期盈利3.31億元;歸屬於上市公司股東的扣除非經常性損益的淨虧損20.81億元,上年同期盈利2.05億元;基本每股虧損2.11元。
公司所處行業為醫藥製造業,主要從事醫藥產品的研發、生產與銷售。公司及子公司產品涵蓋抗腫瘤、微生物、心腦血管、清熱解毒、消化系統、骨骼肌肉系統、婦科系統、神經系統等多個領域。母公司的主導產品主要包括複方嗜酸乳桿菌片、風濕祛痛膠囊、消癌平注射液、芩石利咽口服液等。子公司聖泰生物經營的品種主要集中在骨多肽類、腦保護劑化學藥、心腦血管中成藥、清熱解毒類以及兒童呼吸系統中成藥等五類藥品領域,在同類產品零售市場建立了一定的市場地位,主要產品為骨瓜提取物製劑、小牛血去蛋白提取物製劑、血栓通注射液、清開靈片及小兒熱速清顆粒。子公司永康製藥生產的藥品種類主要系中成藥,用於治療腺體增生、炎性疾病、骨外傷及軟組織損傷等相關疾病,主要產品包括小金丸、天然麝香小金丸、消咳喘膠囊、九味羌活顆粒、元胡止痛分散片、温胃舒片等。子公司源首生物主導產品蠟樣芽孢桿菌活菌膠囊、蠟樣芽孢桿菌活菌片為治療用生物活菌微生態製劑,主要用於治療腸炎、腹瀉、嬰幼兒腹瀉及腸功能紊亂。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.